Charles Dockendorff - Haemonetics Independent Director
| HAE Stock | USD 84.88 0.34 0.40% |
Director
Mr. Charles J. Dockendorff serves as independent director of the company. He currently serves as a member of the Keysight Technologies Inc. Board of Directors where he is Chairman of the Audit and Finance Committee and a member of the Nominating and Corporationrationrate Governance Committee. Keysight Technologies is a New York Stock Exchange listed company focused on electronic measurement. In April 2015, Mr. Dockendorff joined the Board of Directors of Boston Scientific Corporation where he serves as a member its Audit and Finance Committees. In May 2016, Mr. Dockendorff assumed the role of Chairman of Boston Scientific Audit Committee. In 2015, Mr. Dockendorff retired from Covidien plc, where he served as Executive Vice President and Chief Financial Officer since 2006. The business, formerly known as Tyco Healthcare, separated from parent company Tyco International on June 29, 2007. From 1995 until 2006, Mr. Dockendorff served as Vice President and Chief Financial Officer of Tyco Healthcare. Mr. Dockendorff joined the Kendall Healthcare Products Company, the foundation of the Tyco Healthcare business, in 1989 as Controller and was named Vice President and Controller five years later. He was appointed Chief Financial Officer of Tyco Healthcare in 1995. since 2014.
| Age | 66 |
| Tenure | 10 years |
| Address | 125 Summer Street, Boston, MA, United States, 02110 |
| Phone | 781 848 7100 |
| Web | https://www.haemonetics.com |
Haemonetics Management Efficiency
The company has Return on Asset of 0.0612 % which means that on every $100 spent on assets, it made $0.0612 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1472 %, implying that it generated $0.1472 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Haemonetics' Return On Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.10, whereas Return On Capital Employed is forecasted to decline to 0.06. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 929.4 M, whereas Other Current Assets are forecasted to decline to about 35.8 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Ernest Burgess | National HealthCare | 79 | |
| Jonathan Wheeler | CryoCell International | 55 | |
| Richard LaRoche | National HealthCare | 74 | |
| Charles Elson | Encompass Health Corp | 60 | |
| Andrew Adams | National HealthCare | 72 | |
| Brian Sheehy | CryoCell International | N/A | |
| Edward Shaw | Encompass Health Corp | 73 | |
| Lawrence Tucker | National HealthCare | 75 | |
| Parvinderjit Khanuja | Select Medical Holdings | 62 | |
| Marilyn Tavenner | Select Medical Holdings | 69 | |
| Leslye Katz | Encompass Health Corp | 66 | |
| Emil Hassan | National HealthCare | 72 | |
| Paul Abernathy | National HealthCare | 82 | |
| Leopold Swergold | Select Medical Holdings | 77 | |
| Thomas Scully | Select Medical Holdings | 63 | |
| Christopher Reidy | Encompass Health Corp | 64 | |
| Russell Carson | Select Medical Holdings | 77 | |
| Yvonne Curl | Encompass Health Corp | 65 | |
| John Chidsey | Encompass Health Corp | 58 | |
| Daren Shaw | The Ensign Group | 61 | |
| Katherine Davisson | Select Medical Holdings | 53 | |
Management Performance
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0612 |
Haemonetics Leadership Team
Elected by the shareholders, the Haemonetics' board of directors comprises two types of representatives: Haemonetics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Haemonetics. The board's role is to monitor Haemonetics' management team and ensure that shareholders' interests are well served. Haemonetics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Haemonetics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Susan Hanlon, Chief Accounting Officer and VP of Fin. | ||
| Stewart Strong, Pres Hospital | ||
| Rajeev Varma, Senior Development | ||
| William Burke, Chief Financial Officer, Executive Vice President | ||
| Olga Guyette, Director Relations | ||
| Carla Burigatto, VP Communications | ||
| Laurie Miller, Senior Officer | ||
| Anthony Gazikas, CIO and VP | ||
| Susan Foote, Independent Director | ||
| David Helsel, Executive Vice President - Global Manufacturing | ||
| Seyed Mirsaid, Executive Vice President, Chief Technology Officer | ||
| Ronald Gelbman, Interim CEO, Lead Director, Chairman of Governance and Compliance Committee and Member of Audit Committee | ||
| Robert Abernathy, Independent Director | ||
| Neil Ryding, Executive Vice President Global Operations | ||
| Ellen Zane, Non-Executive Independent Chairman of the Board | ||
| David Wilson, President - Plasma Business Unit | ||
| Sandra Jesse, Vice President Chief Legal Officer | ||
| Kent Davies, COO | ||
| Christopher Lindop, CFO and Executive VP of Bus. Devel. | ||
| Claire Pomeroy, Independent Director | ||
| Michelle Basil, Executive Vice President General Counsel | ||
| Christopher Simon, President, Chief Executive Officer, Director | ||
| Catherine Burzik, Independent Director | ||
| Mark Kroll, Independent Director | ||
| Dan Goldstein, Principal Accounting Officer | ||
| James Darecca, Executive Vice President, Chief Financial Officer | ||
| James CPA, Executive CFO | ||
| Jacqueline Scanlan, Senior Vice President - Human Resources | ||
| Josep Llorens, Senior Vice President - Global Manufacturing and Supply Chain | ||
| Farris Maunsell, Chief VP | ||
| Jonathan White, Chief Science and Technology Officer | ||
| Gerry Gould, IR Contact Officer | ||
| Jan MD, Senior Officer | ||
| Richard Meelia, Non-Executive Independent Chairman of the Board | ||
| Anila Lingamneni, Executive Vice President, Chief Technology Officer | ||
| Francis Tan, Sr Planning | ||
| Byron Selman, President - Global Markets | ||
| Charles Dockendorff, Independent Director | ||
| Thomas McCurdy, President - Global Plasma | ||
| Said Bolorforosh, Executive Vice President, Chief Technology Officer | ||
| Ronald Merriman, Independent Director | ||
| Pedro Granadillo, Independent Director | ||
| Lloyd Johnson, Director | ||
| Michael Coyle, Independent Director |
Haemonetics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Haemonetics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0612 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 4.99 B | ||||
| Shares Outstanding | 50.79 M | ||||
| Shares Owned By Insiders | 0.76 % | ||||
| Shares Owned By Institutions | 99.24 % | ||||
| Number Of Shares Shorted | 2.04 M | ||||
| Price To Earning | 50.35 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.Note that the Haemonetics information on this page should be used as a complementary analysis to other Haemonetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Haemonetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Earnings Share 2.46 | Revenue Per Share 25.092 | Quarterly Revenue Growth 0.101 | Return On Assets 0.0612 |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.